Ipsen Regulated Information | Investor Relations

Regulated Information
Shareholders Meeting

Period

Filter by

Reset

Showing: 1 – 5 of 179 Regulated Information

Show

Sort

13 May 2026

Ipsen S.A. – Evolution of the composition of the Board of Directors

13 May 2026

Annual General Meeting of Ipsen S.A. held on 13 May 2026

22 April 2026

$Download Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration$

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

03 April 2026

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

01 April 2026

Ipsen announces the availability of its 2025 Universal Registration Document

1 2 3 4 5 6 … 36

Regulated Information

Filter

Ipsen S.A. – Evolution of the composition of the Board of Directors

Annual General Meeting of Ipsen S.A. held on 13 May 2026

Ojemda® approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration

Ipsen announces that Beech Tree has obtained an exemption from the obligation to submit a public tender offer

Ipsen announces the availability of its 2025 Universal Registration Document

We value your feedback